Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids III. Efficacy and safety of unfractionated and high-molecular-weight preparations in rhinoconjunctivitis and asthma

Bousquet, Jean; Maasch, H.J.; Hejjaoui, A.; Skassa-Brociek, W.; Wahl, Rüdeiger; Dhivert, H.; Michel, François‐Bernard

doi:10.1016/0091-6749(89)90369-2

Cited by 103 publications

(44 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the past, when patients received immunotherapy with allergoids, which represent chemically denatured allergen extracts with reduced IgE reactivity, side-effects and, in particular, late-phase side-effects were still observed despite a reduction of IgE reactivity (Table 1) [69,70]. The unambiguous demonstration of non-IgE-mediated sideeffects was given, observing patients who had received T cell epitope-containing peptides without IgE reactivity.…”

Section: Factors Limiting the Broad Application Of Allergen-specific mentioning

confidence: 99%

See 1 more Smart Citation

Developments in allergen‐specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen‐specific immunoglobulin E and T cell reactivity

Focke

Swoboda

Marth

et al. 2010

Clin Experimental Allergy

101

View full text Add to dashboard Cite

SummaryAllergen-specific immunotherapy (SIT) is the only specific and disease-modifying approach for the treatment of allergy but several disadvantages have limited its broad applicability. We argue that the majority of the possible disadvantages of SIT such as unwanted effects, poor efficacy and specificity as well as inconvenient application are related to the poor quality of natural allergen extracts, which are the active ingredients of all currently available allergy vaccines. Because of the progress made in the field of molecular allergen characterization, new allergy vaccines based on recombinant allergens, recombinant hypoallergenic allergen derivatives and allergen-derived T cell peptides have entered clinical testing and hold promise to reduce the side-effects and to increase the specificity as well as the efficacy of SIT. Here, we present a refined immunotherapy concept, which is based on the use of peptides derived from allergen surfaces that exhibit reduced, allergen-specific IgE as well as T cell reactivity. These peptides when fused to non-allergenic carriers give rise to allergen-specific protective IgG responses with T cell help from a non-allergenic carrier molecule. We summarize the experimental data demonstrating that such peptide vaccines can bypass allergen-specific IgE as well as T cell activation and may be administered at high doses without IgE-and T cell-mediated side-effects. Should these peptide vaccines prove efficacious and safe in clinical trials, it may become possible to develop convenient, safe and broadly applicable forms of SIT as true alternatives to symptomatic, drug-based allergy treatment.

show abstract

Section: Factors Limiting the Broad Application Of Allergen-specific mentioning

confidence: 99%

“…The IgE reactivity of the allergen extracts was reduced by denaturation using aldehydes resulting in allergoids [69,70,77,78], by proteolysis [79][80][81] or by conjugation of the extracts to chemical groups (e.g. using mPEG) [82,83].…”

Section: Past and Present Attempts For The Improvement Of Allergen-spmentioning

confidence: 99%

Developments in allergen‐specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen‐specific immunoglobulin E and T cell reactivity

Focke

Swoboda

Marth

et al. 2010

Clin Experimental Allergy

101

View full text Add to dashboard Cite

show abstract

“…TTie characteristics of studies evaluating immunotherapy in asthma (37,(48)(49)(50)(51)(52)(53)(54)(55)(56)(57)(58)(59)(60)(61)(62) by symptom/medication scores are shown in Table 2. The efficacy of grass-pollen immunotherapy has been investigated in six studies (37,48,52,(54)(55)(56) and documented in five.…”

Section: Clinical Efficacy In Asthmamentioning

confidence: 99%

“…These studies can be subdivided into 13 studies (5,7,9,11,12,15,17,19,22,32,35,36,39) investigating ragweed allergy (nine showing clinically relevant efficacy, i.e., symptom/medication scores diminished by >30% in the actively treated). Fifteen studies investigated the efficacy of immunotherapy in grass-pollen allergy (8,13,16,18,20,21,23,25,30,34,37,38,40,44,47), of which 14 proved efficacy. Nine studies investigated other pollen allergens: mountain cedar (10,27,29), Parietaria (42,43,46), Cupressus (45), Cocos (41), and mixtures (6); efficacy was demonstrated in six.…”

Section: Clinical Efficacy Of Immunotherapy In Rhinitismentioning

confidence: 99%